{"id":6779,"date":"2014-06-10T12:40:49","date_gmt":"2014-06-10T11:40:49","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=6779"},"modified":"2014-06-10T12:40:49","modified_gmt":"2014-06-10T11:40:49","slug":"els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","title":{"rendered":"Los farmac\u00e9uticos profundizan en conocimientos sobre enfermedades minoritarias: LMA y enfermedad de Castleman"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-6783 alignleft\" alt=\"cofb.140603-05\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/06\/cofb.140603-05.jpg\" width=\"367\" height=\"245\" \/><strong>Las enfermedades minoritarias pueden afectar a un 5-7% de la poblaci\u00f3n general y la estimaci\u00f3n es que hay unos 30 millones de afectados en la Uni\u00f3n Europea, unos tres millones en el Estado espa\u00f1ol y cerca de 400.000 en Catalu\u00f1a<\/strong>. Profundizar en el conocimiento de estas enfermedades, conocer los aspectos cl\u00ednicos y de tratamiento de la leucemia mieloide aguda (LMA), dar a conocer las posibilidades de tratamiento en la enfermedad de Castleman aprobadas hace poco tiempo por la FDA, conseguir una opini\u00f3n de la visi\u00f3n que la industria farmac\u00e9utica da de este grupo de patolog\u00edas y el papel de algunos tratamientos en la terap\u00e9utica son los objetivos de la sesi\u00f3n que acogi\u00f3 el Colegio \u201c<strong>Enfermedades minoritarias: LMA y enfermedad de Castleman, dos ejemplos de avances terap\u00e9uticos<\/strong>\u201d coordinada por Tom\u00e0s Casas\u00edn, vocal de Hospitales del Colegio, Roser Vall\u00e8s, vocal de Atenci\u00f3n Primaria, y Julio Mart\u00ednez, presidente de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC).<\/p>\n<p>El curso trat\u00f3 <b>aspectos cl\u00ednicos de la leucemia mieloide aguda (LMA<\/b>) y abord\u00f3 la situaci\u00f3n actual del <b>tratamiento dada la reclasificaci\u00f3n reciente de los criterios diagn\u00f3sticos<\/b>, hecho que modifica las opciones terap\u00e9uticas y determina nuevos criterios terap\u00e9uticos. Tambi\u00e9n expuso los puntos de vista de la industria farmac\u00e9utica en relaci\u00f3n con estas enfermedades y, en cuanto a la <b>enfermedad de Castleman<\/b>, se present\u00f3 la <b>novedad terap\u00e9utica recientemente aprobada por la FDA<\/b> para el tratamiento de la enfermedad y que supone un incremento de la supervivencia global de estos pacientes.<\/p>\n\n<p>La formaci\u00f3n, <strong>dirigida a farmac\u00e9uticos de hospitales y de centros de atenci\u00f3n primaria<\/strong>, cont\u00f3 con el patrocinio de <a href=\"http:\/\/www.janssen.es\/\">Janssen<\/a>. El equipo docente de este curso, dirigido por M. Queralt Gorgas, farmac\u00e9utica del Hospital Universitario Parc Tauli (Sabadell), estuvo formado por:<\/p>\n<ul>\n<li>Salud Brunet, hemat\u00f3loga del Servicio Hematolog\u00eda del Hospital de Sant Pau e investigadora del Instituto de Investigaci\u00f3n Biom\u00e9dica Sant Pau (Barcelona).<\/li>\n<li>Ignacio Garcia, responsable de Market Acces de Janssen.<\/li>\n<li>Sara Vidal, farmac\u00e9utica del departamento de Medical Affairs de Janssen.<\/li>\n<\/ul>\n<h5 style=\"text-align: right;\"><span style=\"color: #999999;\">Con el patrocinio de:<\/span><\/h5>\n<p align=\"right\"><a href=\"http:\/\/www.janssen.es\/\"><img decoding=\"async\" class=\"alignright size-full wp-image-6780\" alt=\"janssen_logo\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2014\/06\/janssen_logo.jpg\" width=\"100\" height=\"49\" \/><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Las enfermedades minoritarias pueden afectar a un 5-7% de la poblaci\u00f3n general y la estimaci\u00f3n es que hay unos 30 millones de afectados en la Uni\u00f3n Europea, unos tres millones en el Estado espa\u00f1ol y cerca de 400.000 en Catalu\u00f1a. Profundizar en el conocimiento de estas enfermedades, conocer los aspectos cl\u00ednicos y de tratamiento [\u2026]<\/p>","protected":false},"author":1,"featured_media":6783,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[70],"class_list":["post-6779","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-formacio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-10T11:40:49+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman\",\"datePublished\":\"2014-06-10T11:40:49+00:00\",\"dateModified\":\"2014-06-10T11:40:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Formaci\u00f3\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\",\"name\":\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2014-06-10T11:40:49+00:00\",\"dateModified\":\"2014-06-10T11:40:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","og_locale":"es_ES","og_type":"article","og_title":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2014-06-10T11:40:49+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman","datePublished":"2014-06-10T11:40:49+00:00","dateModified":"2014-06-10T11:40:49+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage"},"thumbnailUrl":"","keywords":["Formaci\u00f3"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","url":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/","name":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage"},"thumbnailUrl":"","datePublished":"2014-06-10T11:40:49+00:00","dateModified":"2014-06-10T11:40:49+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2014\/06\/10\/els-farmaceutics-aprofundeixen-coneixements-sobre-malalties-minoritaries-lma-i-malaltia-de-castleman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Els farmac\u00e8utics aprofundeixen coneixements sobre malalties minorit\u00e0ries: LMA i malaltia de Castleman"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Les malalties minorit\u00e0ries poden afectar un 5-7% de la poblaci\u00f3 general i l\u2019estimaci\u00f3 \u00e9s que hi ha uns 30 milions d\u2019afectats a la Uni\u00f3 Europea, uns tres milions a l\u2019Estat espanyol i prop de 400.000 a Catalunya. Aprofundir en el coneixement d\u2019aquestes malalties, con\u00e8ixer els aspectes cl\u00ednics i de tractament [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/6779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=6779"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/6779\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=6779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=6779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=6779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}